Benefits
Erectile Dysfunction (One Small RCT)
The Cherdshewasart 2003 randomized double-blind clinical trial in Thai males aged 30-70 with ED showed significant improvement in 4 of 5 IIEF-5 questionnaire domains over 3 months. 82.4% of patients reported noticeable improvement. Hematology and blood chemistry showed no apparent change. Important: small single-trial evidence — not replicated in larger Western populations.
Possible cAMP PDE Inhibition (Mechanism for ED Effect)
Compounds isolated from Butea superba tuber show inhibitory effects on cAMP phosphodiesterase higher than caffeine and theophylline in vitro. This mechanism overlaps with PDE5 inhibitors (sildenafil) for erectile function — though specific PDE5 selectivity is unclear. Mechanism-based explanation for the ED trial findings.
Possible Androgenic / Phytoandrogen Activity
Animal studies (Malaivijitnond 2010) and the Chaiyasit 2012 human case report document androgen elevation — specifically dihydrotestosterone (DHT) increases. The 2012 case showed DHT 1512 pg/mL (reference 250-990) after 'a few weeks' of Butea capsules. This has been characterized BOTH as a desired effect (for libido) AND as an adverse hyperandrogenism event.
Traditional Thai Use for Vitality
Known as Red Kwao Krua in Thailand, Butea superba is traditionally classified as a 'rejuvenating' herb for aging men, paralleling Pueraria mirifica (White Kwao Krua) for women. Used historically to promote vitality, libido, and physical strength. Most evidence remains traditional rather than RCT-confirmed.
Possible Improved Penile Blood Flow (Animal)
Diabetic rat studies show Butea superba enhanced penile erection by increasing intracavernous pressure (ICP), explained by relaxation of cavernous smooth muscle and increased blood flow. Provides preclinical mechanism for ED benefit beyond cAMP PDE inhibition.
Mechanism of action
cAMP Phosphodiesterase Inhibition
Butea superba tuber compounds inhibit cAMP phosphodiesterase more potently than methylxanthines (caffeine, theophylline) in vitro. Elevated cAMP supports smooth muscle relaxation in cavernous bodies — a mechanism related to (but distinct from) cGMP-PDE5 inhibition by sildenafil. May explain ED benefits.
Androgenic / DHT-Elevating Activity
Animal and human case data document increased dihydrotestosterone (DHT) levels with Butea superba use. Mechanism is incompletely understood — may involve LH suppression alongside direct androgenic phytochemicals or 5α-reductase modulation. The 2012 Chaiyasit case showed DHT at 1512 pg/mL (vs. normal 250-990).
Luteinizing Hormone (LH) Reduction
Malaivijitnond 2010 showed Butea superba reduced LH levels in male rats, consistent with negative feedback from elevated peripheral androgens. This is a typical pattern in androgen-elevating agents and may reduce endogenous testicular function with chronic use.
Cavernous Smooth Muscle Relaxation
Beyond cAMP PDE inhibition, animal studies suggest direct relaxant effects on cavernous smooth muscle, supporting penile blood flow increase. This is the proximal mechanism for erectile improvement in animal models.
Phytoestrogen / Phytoandrogen Crosstalk
Butea superba contains both estrogenic (formononetin, flavonoid) and androgenic compounds. The net hormonal effect is androgen-dominant in standard doses. This dual-receptor activity complicates risk assessment, particularly for hormone-sensitive conditions.
Clinical trials
3-month randomized, double-blind clinical trial in Thai males with erectile dysfunction. Crude preparation of Butea superba tubers vs. placebo. Outcomes: IIEF-5 (5-item International Index of Erectile Function) questionnaire and sexual records, plus safety hematology and blood chemistry. (Cherdshewasart, Nimsakul 2003, Asian J Androl)
Thai male volunteers aged 30-70 with erectile dysfunction.
Significant improvement in 4 of 5 IIEF-5 questionnaire domains. Sexual record evaluation indicated 82.4% of patients reported noticeable improvement. Hematology and blood chemistry showed no apparent toxicity over 3 months. Authors concluded the plant preparation appears to improve erectile function in ED patients without apparent toxicity at the dose and duration studied.
First reported case of hyperandrogenemia due to ingestion of Butea superba supplement. 35-year-old Thai male (no underlying disease, normal prior baseline) presented with significantly increased sexual drive after taking locally-made Butea superba capsules for 'a few weeks' (initial purpose: hair loss treatment). Laboratory workup performed. (Chaiyasit, Wiwanitkit 2012, Indian J Endocrinol Metab)
Single case: Thai single male, aged 35, no underlying disease.
Dihydrotestosterone (DHT) 1512 pg/mL vs. reference range 250-990 pg/mL — significantly elevated. Other findings: DHEA-S 328 μg/dL, free testosterone 1.7%, SHBG 43.24 nmol/L. Diagnosis: hyperandrogenemia from external phytoandrogen source. **First case report establishing that Butea superba can produce clinically significant hyperandrogenemia in healthy males**. Authors noted prior literature also documented genotoxicity at large doses.
About this ingredient
Butea superba (known in Thailand as Red Kwao Krua) is a leguminous climbing plant native to Thailand and Southeast Asia. The medicinally-used part is the tuber root. It is traditionally classified alongside Pueraria mirifica (White Kwao Krua) and Mucuna collettii (Black Kwao Krua) as a 'Kwao Krua' rejuvenating tonic.
Bioactives include flavonoids (medicarpin, formononetin, butein, butin), sterols (β-sitosterol, stigmasterol), and various phenolic compounds. The principal pharmacological mechanisms are cAMP phosphodiesterase inhibition and androgenic/DHT-elevating activity. EVIDENCE: One small RCT (Cherdshewasart 2003) supports erectile dysfunction benefit; preclinical animal studies support penile blood flow effects.
**Critical safety signal**: the Chaiyasit 2012 hyperandrogenemia case report documented clinically significant DHT elevation (1512 pg/mL vs. 250-990 normal range) from typical supplemental use. SAFETY: Possible androgenic adverse effects — relevant for prostate health, hair loss (paradoxically), and hormone-sensitive conditions.
Animal toxicity studies show liver enzyme elevations and other biochemical changes at higher doses. AVOID in women, pregnancy, hormone-sensitive cancers. NOT a first-line approach for ED — consider PDE5 inhibitors (proven efficacy and safety profile) under physician guidance instead.